An update on the use of lenalidomide for the treatment of multiple myeloma

Bibliography

• Harousseau JL, Dreyling M; ESMO Guidelines Working Group. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl 4):97-9
   PubMed Web of Science ®Google Scholar
• Available from: http://seer.cancer.gov/statfacts/html/
   Google Scholar
• Richardson RG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with multiple myeloma. Blood 2002;100(9):3063-7
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357(21):2133-42
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357(21):2123-32
   PubMed Web of Science ®Google Scholar
• Benboubker L, Dimopoulos MA, Dispenzieri A, et al. FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014;371(10):906-17
   PubMed Web of Science ®Google Scholar
• Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009;12(2):36
   Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-16
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24(1):22-32
   PubMed Web of Science ®Google Scholar
• Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003;17:41-4
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525-30
   PubMed Web of Science ®Google Scholar
• Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008;22:1925-32
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118:4771-9
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M, et al. MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759-69
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1770-81
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1782-91
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, et al. Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29-37
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014;371(10):895-905
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008;111(3):1101-9
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Griffith KA, Reece DE, et al. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 multiple myeloma research consortium trial. Blood 2011;118(3):535-43
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lacy MQ, Hayman SR, et al. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol 2011;86(8):640-5
   PubMed Web of Science ®Google Scholar
• Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108(10):3458-64
   PubMed Web of Science ®Google Scholar
• Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009;114(4):772-8
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide Lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147-52
   PubMed Web of Science ®Google Scholar
• Alegre A, Aguado B, Giraldo P, et al. Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. Int J Hematol 2011;93(3):351-60
   PubMed Web of Science ®Google Scholar
• Spina F, Montefusco V, Crippa C, et al. Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. Leuk Lymphoma 2011;52(7):1262-70
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Weber DM, Niesvizky R, et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 2009;82(6):426-32
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Dimopoulos MA, Wang M, et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010;95(10):1738-44
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Weber DM. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 2011;11(1):38-43
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Dimopoulos MA, Stadtmauer EA, et al. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 2011;11(1):38-43
   PubMed Web of Science ®Google Scholar
• Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008;112(12):4445-51
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Beksac M, Benboubker L, et al. Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica 2013;98(8):1264-72
   PubMed Web of Science ®Google Scholar
• Richardson PG, Xie W, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood 2014;123(10):1461-9
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Christoulas D, et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010;24(10):1769-78
   PubMed Web of Science ®Google Scholar
• Berenson JR, Yellin O, Kazamel T, et al. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Leukemia 2012;26(7):1675-80
   PubMed Web of Science ®Google Scholar
• Wang M, Martin T, Bensinger W, et al. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 2013;122(18):3122-8
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Martin TG, Bensinger WI, et al. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res 2013;19(8):2248-56
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012;120(9):1801-9
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372(2):142-52
   PubMed Web of Science ®Google Scholar
• Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. J Clin Oncol 2014;32(25):2712-17
   PubMed Web of Science ®Google Scholar
• Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119(19):4375-82
   PubMed Web of Science ®Google Scholar
• Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol 2014;15:1503-12
   PubMed Web of Science ®Google Scholar
• Palumbo A, Larocca A, Falco P, et al. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. Leukemia 2010;24(5):1037-42
   PubMed Web of Science ®Google Scholar
• Shah JJ, Orlowski RZ, Alexanian R, et al. Phase I trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed/refractory multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts) 2010;116(21):1948
   Google Scholar
• Mark TM, Bowman IA, Rossi AC, et al. Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leuk Lymphoma 2014;55(12):2842-9
   PubMed Web of Science ®Google Scholar
• Tufail M, Siegel DS, McBride L, et al. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk 2012;12(3):186-90
   PubMed Web of Science ®Google Scholar
• Knop S, Gerecke C, Liebisch P, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009;113(18):4137-43
   PubMed Web of Science ®Google Scholar
• Baz R, Walker E, Karam MA, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006;17(12):1766-71
   PubMed Web of Science ®Google Scholar
• Reece DE, Masih-Khan E, Khan A, et al. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide (Revlimid(R)) (CPR) for the treatment of patients with relapsed and refractory multiple myeloma [abstract]. Blood 2010;116(21):3055
   Google Scholar
• Lentzsch S, O’Sullivan A, Kennedy R, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with refractory or relapsed multiple myeloma is safe and highly effective: results of phase I/II open-label, dose escalation study [abstract]. Blood (ASH Annual Meeting Abstracts) 2011;118(21):304
   Web of Science ®Google Scholar
• Schey SA, Morgan GJ, Ramasamy K, et al. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Br J Haematol 2010;150(3):326-33
   PubMed Web of Science ®Google Scholar
• Raje N, Kumar S, Hideshima T, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004;104(13):4188-93
   PubMed Web of Science ®Google Scholar
• Hofmeister CC, Yang X, Pichiorri F, et al. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol 2011;29(25):3427-34
   PubMed Web of Science ®Google Scholar
• Mahindra A, Richardson PG, Hari P, et al. Updated results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma with pharmacodynamic and pharmacokinetic analysis [abstract]. Blood (ASH Annual Meeting Abstracts) 2010;116(21):3051
   Google Scholar
• Richter JR, Bilotti E, McBride L, et al. Salvage therapy with vorinostat, lenalidomide, and dexamethasone (ZRD) in lenalidomide/dexamethasone relapsed/refractory multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts) 2011;118(21):3986
   Web of Science ®Google Scholar
• Jakubowiak AJ, Richardson PG, Zimmerman TM, et al. Final phase I results of perifosine in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts) 2010;116(21):3064
   PubMed Web of Science ®Google Scholar
• Lonial S, Jagannath S, Moreau P, et al. Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety. J Clin Oncol 2013;Abstract 8542
   Google Scholar
• Berdeja JG, Ailawadhi S, Niesvizky R, et al. Phase I study of lorvotuzumab mertansine (IMGN901) in combination with lenalidomide and dexamethasone in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma – a preliminary safety and efficacy analysis of the combination [abstract]. Blood (ASH Annual Meeting Abstracts) 2010;116(21):1934
   Web of Science ®Google Scholar
• Agura E, Niesvizky R, Matous J, et al. Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a phase 1b study [abstract]. Blood (ASH Annual Meeting Abstracts) 2009;114(22):2870
   Web of Science ®Google Scholar
• Zhang S, Liang J, Chen L, et al. Enhanced NK cell mediated cytotoxicity against multiple myeloma (MM) cells by the combination of anti-KIR (1-7F9) monoclonal antibody (mAb) and lenalidomide [abstract]. Proceedings of 2nd AACR Annual Meeting Abstracts; 2009. p. 3245
   Google Scholar
• Plesner T, Arkenau HT, Lokhorst HM, et al. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. J Clin Oncol 2014;32(5s):Abstract 8533
   Google Scholar
• Mateos M, Spencer A, Taylor K, et al. Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). ASCO Annual Meeting Abstracts; 2010. 28(15S):Abstract 8030
   Google Scholar
• Siegel DS, Richardson P, Dimopoulos M, et al. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer J 2014;4:e182
   PubMed Web of Science ®Google Scholar
• Bahlis NJ, Mansoor A, Lategan JC, et al. Lenalidomide overcomes poor prognosis conferred by deletion of chromosome 13 and t(4;14) in multiple myeloma: MM016 trial. Blood (ASH Annual Meeting Abstracts) 2006;108:Abstract 3557
   Google Scholar
• Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009;146:164-70
   PubMed Web of Science ®Google Scholar
• Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone:adverse effect of deletion 17p13. Blood 2009;114:522-5
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Soulier J, Fermand JP, et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010;24:623-8
   PubMed Web of Science ®Google Scholar
• Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009;114:518-21
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Caillot D, Marit G, et al. Longterm maintenance with lenalidomide improves progression free survival in myeloma patients with high-risk cytogenetics: an IFM study [abstract]. Blood (ASH Annual Meeting Abstracts) 2010;116(21):1944
   Google Scholar
• Nooka AK, Kaufman JL, Muppidi S, et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 2014;28(3):690-3
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Christoulas D, Roussou M, et al. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol 2010;85(1):1-5
   PubMed Web of Science ®Google Scholar
• Weber D, Wang M, Chen C, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. Blood (ASH Annual Meeting Abstracts) 2006;108:Abstract 3547
   Google Scholar
• Klein U, Neben K, Hielscher T, et al. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol 2011;90(4):429-39
   PubMed Web of Science ®Google Scholar
• de la Rubia J, Roig M, Ibanez A, et al. Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study. Eur J Haematol 2010;85(4):363-5
   PubMed Web of Science ®Google Scholar
• Masini L, Hernandez M, Hajek R, et al. An update on the overall safety and incidence of SPM in lenalidomide, thalidomide, and bortezomib-treated patients within the European post-Approval Safety Study (EU PASS) of relapsed/refractory MM. Haematologica 2012;97(Suppl1):340; abstract 0831
   PubMed Web of Science ®Google Scholar
• Gao M, Gao L, Yang G, et al. Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials. Int J Clin Exp Pathol 2014;7(6):3073-80
   PubMed Web of Science ®Google Scholar
• Lonial S, Baz R, Swern AS, et al. Neutropenia is a predictable and early event in affected patients with relapsed/refractory multiple myeloma treated with lenalidomide in combination with dexamethasone. Blood 2009;114:abstract 2879
   Web of Science ®Google Scholar
• De Luisi A, Ferrucci A, Coluccia AM, et al. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res 2011;17(7):1935-46
   PubMed Web of Science ®Google Scholar
• Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010;116(26):5838-41
   PubMed Web of Science ®Google Scholar
• Carrier M, Le Gal G, Tay J, et al. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011;9(4):653-63
   PubMed Web of Science ®Google Scholar
• Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98(10):708-14
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, et al. International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22(2):414-23
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012;119(12):2764-7
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 2014;15(3):333-42
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide Maintenance After Stem-Cell Transplantation For Multiple Myeloma: Follow-Up Analysis Of The IFM 2005-02 Trial [Abstract 406]. Proceedings of 55th ASH Annual Meeting and Exposition; 7-10 December 2013; New Orleans, LA
   Google Scholar
• McCarthy P, Owzar K, Hofmeister C, et al. Analysis of Overall Survival (OS) in the Context of Cross-Over from Placebo to Lenalidomide and the Incidence of Second Primary Malignancies (SPM) in the Phase III Study of Lenalidomide Versus Placebo Maintenance Therapy Following Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM) CALGB (Alliance) ECOG BMTCTN. Clinical Lymphoma Myeloma and Leukemia 2013;13(Suppl S28):S15-15
   PubMed Web of Science ®Google Scholar
• Holstein SA, Owzar K, Richardson PG, et al. Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM). J Clin Oncol 2015;33(Suppl):Abstract 8523
   Google Scholar
• Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 2011;118(15):4086-92
   PubMed Web of Science ®Google Scholar